Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
This predictive technology empowers people with diabetes to take preventive action before complications arise
Merck opens first climate-neutral manufacturing facility in Ireland
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Subscribe To Our Newsletter & Stay Updated
